The association between three cyclooxygenase-2 polymorphisms and hepatocellular carcinoma risk: a meta-analysis.
BACKGROUND
A quantity of case-control studies have been performed to address the association between three cyclooxygenase-2(COX-2) polymorphisms (-1195G/A, -765G/C and +8473T/C) and the risk of hepatocellular carcinoma (HCC). However, previous research results are inconsistent. We conducted this meta-analysis to clarify the correlation between these COX-2 polymorphisms and HCC risk.


METHODS
The authors searched in PubMed, EMBASE, Google Scholar, CNKI and WanFang database for relevant articles up to April 28, 2014. The data were extracted by two independent reviewers. Odds ratios (ORs) and 95% confidence intervals were calculated.


RESULTS
A total of 8 studies consisting of 2182 cases and 3324 controls were included in this meta-analysis. For COX-2 polymorphism -1195G/A, an association with increased risk was observed under the heterogeneous, homozygous, dominant model. However, COX-2 polymorphisms (-765G/C and +8473T/C) were not related to HCC risk in this study. We also found a similar result in the subgroup analysis of Chinese population that -1195G/A polymorphism, instead of -765G/C or +8473T/C polymorphism, was correlated with the risk of HCC.


CONCLUSIONS
Polymorphism -1195G/A of COX-2 might be associated with susceptibility to HCC, but no similar correlations were observed between polymorphisms (-765G/C and +8473T/C) and HCC risk. Further large and well-designed studies are required to validate this association.
Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University, Nanning, P.R.China.
Zhigang
Z
Chen
Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University, Nanning, P.R.China.
Jiye
J
Zhu
Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University, Nanning, P.R.China.
Chaoyuan
C
Huang
Physiology Department, Guangxi Medical University, Nanning, P.R.China.
Fang
F
Lian
Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University, Nanning, P.R.China.
Guobin
G
Wu
Hepatobiliary Surgery Department, Tumor Hospital of Guangxi Medical University, Nanning, P.R.China.
Yinnong
Y
Zhao
D000483:Alleles; D006528:Carcinoma, Hepatocellular / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000235:genetics* / Q000378:metabolism; D016208:Databases, Factual; D004198:Disease Susceptibility; D005006:Ethnicity / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
D051546:Cyclooxygenase 2